### **Interesting Cases in Infectious Diseases**

Kristine Anne Scordo PhD, ACNP-BC, FAANP TriHealth Hospitals, Cincinnati, Ohio Professor Emeriti Wright State University, CoNH

All pictures are from clinical practice



### Disclosures

- Kristine A Scordo, PhD, RN, ACNP-BC, FAANP has no financial relationships with commercial interests to disclose
- Any unlabeled/unapproved uses of drugs or products referenced will be disclosed



### Objectives

Correctly interpret various diagnostic testing in infectious diseases

Discuss identification of various infectious diseases

Discuss treatment measures for various infectious diseases

## Case Study

- A 67-year-old female presents to ED with c/o frequent urination which is "chronic." She denies fever, flank pain, chills, but has some frequency. She states she knows she has a UTI and insists on being treated, because her "doctor" always does. She was told that she has "chronic UTI"
- She has pain with sexual intercourse and (+++) vaginal dryness
- She has 6 Ucxs during the last 6 months and the dysuria frequency " does not go away…"
- Her urinalysis showed +small leucocyte esterase, (-) nitrites, 5-10 wbc/hpf
- Her urine cx is as follows.....

MADDATET



URINE UNSPECIFIED				
CULTURE RESULTS				
10,000 - 100,000 C	FU/ML ENTER	OCOCCUS FAECIUM	Infection Prevention A	lert
CULTURE RESULTS				
			fication and susceptibi	lity per
current Evidenced	Based Guide	lines.		
CULTURE RESULTS				
Tested at Bethesda	Oak Labora	tory 619 Oak St	reet 45206	
REPORT STATUS 03/25/2016 FINAL R	EPORT			
ORGANISM				
ENTEROCOCCUS FAECI	UM			
Culture & Susceptibility				
ENTEROCOCCUS F	AECIUM			
Antibiotic		Sensitivity	Microscan	Status
Ampicillin		Resistant	>8 RESISTANT	Final
	Method:	MIC		
Ciprofloxacin		Resistant	>2 RESISTANT	Final
	Method:	MIC		
Daptomycin		Sensitive	4 SUSCEPTIBLE	Final
6.220 MIL 01427-024 CP144-014	Method:			
Levofloxacin	1.220101111	Resistant	>4 RESISTANT	Final
	Method.			
Linezolid		Sensitive	2 SUSCEPTIBLE	Final
	Method:			
Nitrofurantoin		Sensitive	<=32 SUSCEPTIBLE	Final
	Method.	100	SUSCEPTIBLE	
Tetracycline	HALL BOAL	Resistant	>8 RESISTANT	Final
retracycline	Method		- Theoreman	( IIIOI
Vancomycin	HILL LOUG	Resistant	>16 RESISTANT	Final
Tanconyon		realizer	PLEASE NOTE VANCOMYCIN RESISTANCE	1 mar
	Method:	MIC		
Comments ENTEROCO 10,000 - 1			S FAECIUM Infection Preventio	n Alert

From clinical practice



Туре	Urine, clean		16 1328	$\supset$	B
mponents					
Color, UA	DK YELLOW	St:aw/Yellow		-	Lab Fairfiel d
Clarity, UA	Clear	Clear		-	Fairfiel d
Glucose, Ur	Negative	Negative mg/dL		-	Fairfiel
Bilirubin Urine	Negative	Negative			Fairfiel
Ketones, Urine	Negative	Negative mg/dL		-	Fairfiel
Specific Gravity, UA	1.011	1.005-1.030			Fairfiel d
Blood, Urine	Negative	Negative		-	Fairfiel
pH, UA	7.0	5.0-8.0		•	Fairfiel
Protein, UA	TRACE	Negative mg/dL	A		Fairfiel
Urobilinogen, Urine	1.0	<2.0 E.U./dL		-	Fairfiel
Nitrite, Urine	Negative	Negative		•	Fairfiel
Leukocyte Esterase, Urine	SMALL	Negative	A	-	Fairfiel d
Bacteria, UA	Vaiue RARE	Ref range /HPF	Fiag A	Comment -	Lab Fairfiel
Hyaline Casts, UA	3	0 · 8 /HPF		-	d Fairfiel d
WBC, UA	30	0 - 5 /HPF	м	•	Fairfiel
RBC, UA	3	0 4 /HPF			Fairfiel
Epi Cells	2	0 - 5 /HPF			Fairfiel

### You would do which of the following?

- Give her a 7-day supply of ciprofloxacin (Cipro)
- You put a PICC line and give 10 days of Daptomycin
- You give a 7 day course of Linezolid
- Give her a 5-day supply of trimethoprim/sulfamethoxazole (Bactrim)
- Provide reassurance and
  - a trial of vaginal estrogens
  - urologic studies to rule out overactive bladder
  - Uqura®



## Factoids

Frequently patients are misdiagnosed as "chronic UTI" when, in fact, is asymptomatic bacteriuria

Patients are treated with multiple courses of abx-→ MDR / C.diff / adverse effects / frustration / increased in the healthcare costs---→ BAD QUALITY CARE

Dysuria DOES NOT always means UTI-- $\rightarrow$  menopause / overactive bladder / local candida dermatitis --- $\rightarrow$  TAKE A GOOD HISTORY!

Pyuria DOES NOT always means UTI

Malodor DOES NOT always means a UTI



# Factoids

(+) Nitrites DOES NOT ALWAYS means a UTI-- $\rightarrow$  it tells you that you have bacterias in the urine only (may be just colonizers). Besides, an infection due to Enterococcus will NOT give you positive Nitrites.

Always look @the WBCs-- $\rightarrow$  if there is NO pyuria----> there is NO UTI (regardless of the UC)



- 90 yo female admitted for confusion
- Found to have (+) pyuria and (+) Nitrates
- Can't say if she has dysuria because she has profound dementia
- Found also to have AKI over chronic due to severe dehydration
- The family says that " she usually gets confused when she has a UTI....and DEMANDS abx...".
- She is given IV meropenem and generous IVFs overnight
- The next morning the patient is back to her baseline and more reactive.
- The next morning the daughter tells you: "... I told you, she improves always with IV Abx....".

### Altered mental status and UTI in the elderly

IV. Should ASB Be Screened for and Treated in Functionally Impaired Older Women or Men Residing in the Community, or in Older Residents of Longterm Care Facilities?

### Recommendations

- In older, community-dwelling persons who are functionally impaired, we recommend against screening for or treating ASB (strong recommendation, low-quality evidence).
- 2. In older persons resident in long-term care facilities, we recommend against screening for or treating ASB (strong recommendation, moderate-quality evidence).

IDSA 2019 Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria •

V. In an Older, Functionally or Cognitively Impaired Patient, Which Nonlocalizing Symptoms Distinguish ASB From Symptomatic UTI? *Recommendations* 

- 1. In older patients with functional and/or cognitive impairment with bacteriuria and delirium (acute mental status change, confusion) and without local genitourinary symptoms or other systemic signs of infection (eg, fever or hemodynamic instability), we recommend assessment for other causes and careful observation rather than antimicrobial treatment (strong recommendation, very low-quality evidence).
- 2. In older patients with functional and/or cognitive impairment with bacteriuria and without local genitourinary symptoms or other systemic signs of infection (fever, hemodynamic instability) who experience a fall, we recommend assessment for other causes and careful observation rather than antimicrobial treatment of bacteriuria (strong recommendation, very low-quality evidence). Values and preferences: This recommendation places a high value on avoiding adverse outcomes of antimicrobial therapy such as *Clostridioides difficile* infection, increased antimicrobial resistance, or adverse drug effects, in the absence of evidence that such treatment is beneficial for this vulnerable population. Remarks: For the

# When do you treat asymptotic bacteruria?

### UTI in Pregnancy

- Asymptomatic bacteriuria increases risk of pyelonephritis and has been associated with adverse pregnancy outcomes, such as preterm birth and low birth weight infants
- Treat for 4-7 days
- Follow-up cx done as test of cure ~ one week after completion of therapy
- Recurrent (more than 3 episodes) suppressive therapy
  - Low dose nitrofurantoin (50 -100 mg)
  - Cephalexin (250-500 mg)
  - Can be given postcoital or daily

# UTI in Pregnancy: Choice of Abx

- Remember info was obtained decades ago—little direct info
- Avoid tetracyclines, fluoroquinolones
- Trimethoprim-sulfamethoxazole-limit to mid-pregnancyavoid first trimester and near term
- Avoid trimethoprim in first trimester (folic acid antagonist)
- Fosfomycin-generally safe
- Nitrofurantoin-generally safe

## Upper Respiratory Infection turned to Encephalitis

15

# Case Study

69-year-old male admitted via the ED with mental status changes. He was found to be combative and complaining of back pain.

Per his wife he had been having URI symptoms and treated with Zithromax at Urgent care.

A few days later he starting spiking fevers with mental status changes



11/27/23 05:40	11/26/23 06:50	11/25/23 06:00	11/24/23 06:40	11/23/23 05:11	11/22/23 09:21	11/22/23 04:20	11/21/23 04:41	11/20/23 03:20
8.4	7.0	10.6 ^	11.0 ^	12.9 ^	18.6 ^	17.1 *	22.0 *	16.8 ^
3.59 ¥	3.50 ¥	3.66 ¥	3.62 ¥	3.85 ¥	4.20 ¥	3.67 ¥	3.23 ¥	3.55 ¥
11.8 ¥	11.4 ¥	11.8 ¥	11.5 ¥	12.6 ¥	13.4 ¥	11.9 ¥	10.4 ¥	11.1 ¥
35.0 ¥	34.2 ¥	35.4 ¥	35.1 ¥	38.5 ¥	42.2	36.0 ¥	31.4 ¥	34.8 ¥
97.5 🔺	97.6 🔺	96.7	97.1 ^	99.9 🔺	100.6 🔺	98.0 🔺	97.0	98.2 *
32.9	32.5	32.2	31.8	32.8	31.8	32.5	32.2	31.4
33.8	33.3	33.4	32.7	32.8	31.6 ¥	33.1	33.2	32.0
13.2	13.4	13.2	13.7	14.4	14.9	14.3	14.0	13.8
263	215	192	157	166	147	143	136 🔻	127 ¥
10.1 🖻	10.3 🖻	11.1 🖻	10.7 🖻	10.1 🖻	11.1 🖻	10.0 🖻	10.3 🖻	10.3 🖻

Collected:	11/19/23 2236
Result status:	Final
Resulting lab:	CHEMISTRY NORTH
Reference range	e: 0 - 0.25 ng/mL
Value:	13.95 ^
Comment:	<pre>Interpretation for RESPIRATORY infections (excluding TB, CF, legionella, pseudomonas, acinetobacter stenotrophomonas and empyema/abscess):     &lt;0.1     No bacterial pathology     0.1-0.25     Unlikely bacterial pathology (but must be interpreted in clinical context)     &gt;0.25     Bacterial pathology likely</pre>
	<pre>Interpretation for OTHER infections: Meningitis &lt;0.2 bacterial infection very unlikely Ascites related to liver disease &lt;0.5 spontaneous peritonitis unlikely PCT-based decisions NOT recommended in the following conditions/infections: Pyelonephritis, Osteomyelitis, Endocarditis, HIV, Neutropenia or ESRD</pre>



### Procalcitonin (PCT)

- Procalcitonin (PCT) is a 116-amino acid propeptide expressed in nonneuroendocrine tissues in response to inflammation and cellular injury, particularly in the setting of bacterial sepsis
- Elevated serum levels of PCT upregulated during sepsis correlates with infection severity
- Up to 10 fold increase in patients with AKI/CKD
- Sensitivities range between 0.55 and 0.95 and depend upon various bacteria
  - highest sensitivity in identifying BSI (blood stream infections) due to Streptococcus pneumoniae and Enterobacterales (patients with sepsis 96.4% and 91.3%, and patients without sepsis 88.0% and 86.4%, respectively) and the lowest in identifying BSI due to Enterococci and nonpseudomonal glucose nonfermenters (patients with sepsis 76.7% and 66.7%, and patients without sepsis 58.0% and 58.5%, respectively)\*

LAWANDI, A. et al. Reliability of Admission Procalcitonin Testing for Capturing Bacteremia Across the Sepsis Spectrum: Real-World Utilization and Performance Characteristics, 65 US Hospitals, 2008-2017. CRITICAL CARE MEDICINE, [s. l.], v. 51, n. 11, p. 1527–1537, 2023



Component	3 wk ago				
SPECIMEN DESCRIPTION	BLOOD (SITE 1 PERIPHERAL)				
SPECIMEN TYPE	Blood				
GRAM STAIN RESULTS	GRAM POSITIVE COCCI IN CHAINS				
GRAM STAIN RESULTS	Preliminary critical result called to an				
GRAM STAIN RESULTS	Tested at Bethesda North Hospit				
CULTURE RESULTS	Positive Growth !!				
CULTURE RESULTS	STREPTOCOCCUS PNEUMONIAE				
MICRONOTE	(NOTE) Growth of Streptococcus pneumon:				
REPORT STATUS	11/23/2023 FINAL REPORT				
ORGANISM	STREPTOCOCCUS PNEUMONIAE				
Susceptibility					
	Streptococcus pneumoniae MIC				
Amoxicillin + Clavulanate	<=0.5/0.25 Sensitive <sup>1</sup>				
Azithromycin	<=0.25 Sensitive <sup>1</sup>				
Cefaclor	1 Sensitive <sup>1</sup>				
Cefepime	<=0.25 Sensitive <sup>1</sup>				
Cefuroxime	<=0.25 Sensitive <sup>1</sup>				
Chloramphenicol	<=1 Sensitive <sup>1</sup>				
Clindamycin	<=0.06 Sensitive <sup>1</sup>				
Erythromycin	<=0.06 Sensitive <sup>1</sup>				
Levofloxacin	0.5 Sensitive <sup>1</sup>				
Meropenem	<=0.06 Sensitive <sup>1</sup>				
Penicillin G	<=0.03 Sensitive <sup>1</sup>				
Tetracycline	<=0.5 Sensitive <sup>1</sup>				
Trimethoprim + Sulfamethoxazole	<=0.25/4.7 Sensitive <sup>1</sup>				
Vancomycin	0.5 Sensitive <sup>2</sup>				



TOTAL NUCLEATED CELLS, CSF TOTAL NUCLEATED CELLS, CSF	11/22/23 2,102 ^ 11/22/23 1,545 ^ 🗈	. With mental status change
RBC, CSF	11/22/23 267 *	LP done
	11/22/23 540 ^	
NEUTROPHILS CSF	11/22/23 81 ^	
MONOCYTES CSF	11/22/23 4 🔻 🖻	
LYMPHOCYTES CSF	11/22/23 15 🔻	



# CSF Findings in CNS Infections

	Pressure (40-80mm h2o)	Leukocytes (2-4mm3)	Protein (20-40mg/dl	Glucose (40-80mg/dl)
Bacterial meningitis	increased	100-50000 PMN	100-500 ( high)	Low < 40
Viral meningitis	N or increased	Less than 1000 Mononuclear	50-200( high)	N or high
Viral encephalitis	N or increased	Less than 1000 PMN early, then mononuclear	50-200( high)	N or high
T.B meningitis	increased	10-500 Lymphocytes	100-500 (high)	Low < 40
Brain abscess	increased	10-200 lymphocytes	100- 500	normal



Meningoencephalitis PCR panel	
Status: Final result Visible to patient: No (not released)	Next appt: 12/15/2023 at 09:40 AM in Inte
0 Result Notes	
Component Ref Range & Units	2 wk ago
E. COLI K1 Not Detected	Not Detected
H. INFLUENZAE Not Detected	Not Detected
L. MONOCYTOGENES Not Detected	Not Detected
N. MENINGITIDIS Not Detected	Not Detected
S. AGALACTIAE Not Detected	Not Detected
사실 이 방법 이상 방법 이상 방법 이상 것이다. 이 것이 가지 않는 것이 같이 있는 것이 있는 것이 없는 것이 없 않이	

# S. AGALACTIAE Not Detected S. PNEUMONIA Not Detected Comment: RESULT CALLED TO NURSE DARRYL BRYAN ON 11/22/23 AT 2356 BY 109152. READ BACK YES. CYTOMEGALOVIRUS Not Detected Comment: (NOTE)

The Film Array ME panel does not distinguish between latent and active CMV infection. Detection of this virus may indicate primary infection, secondary reactivation, or the presence of latent virus. Results should always be interpreted in conjunction with other clinical, laboratory and epidemiological information.

ENTEROVIRUS	Not Detected
Not Detected	
HERPES SIMPLEX VIRUS 1	Not Detected
Not Detected	
HERPES SIMPLEX VIRUS 2	Not Detected
Not Detected	
HUMAN HERPESVIRUS 6	DETECTED !!
Not Detected	
Commant DESILT CALLED TO	



Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155960/ Given the rarity of HHV-6 meningitis in immunocompetent adults, there are no established standard treatment guidelines; previous reported cases, as well as this case, suggest that either intravenous ganciclovir or intravenous foscarnet are the most reasonable firstline treatment options.

Another unique feature of the virus is that viral DNA of HHV-6 can be integrated into host chromosomal DNA and inherited through the germline.1 In these individuals, the viral DNA would be present in all nucleated cells and bodily fluids.2 While chromosomally integrated HHV-6 is certainly rare, occurring in only 1% of the population, it can complicate the diagnosis of HHV-6. It is important to note that PCR is reportedly unable to distinguish between active viral replication of DNA vs DNA that was already integrated into the host chromosome.5 While specific tests can differentiate between chromosomally integrated HHV-6 and true HHV-6 meningitis, these tests must be specifically obtained from specialty labs and are not routinely available at most hospitals.



### MRI head

New diffusion restriction within the lateral ventricles and subarachnoid spaces over the high convexities. Differential considerations include intraventricular and subarachnoid hemorrhage or purulent material. Correlation with recent lumbar puncture recommended.

### MRI review by neurology

MRI brain reviewed and agree there is small amount of diffusion restriction within the lateral ventricles. No

hydrocephalus. No focal abscess.

Given hx of strep meningitis findings most likely represent small amount of ventriculitis. Agree with recommendation for longer period of antibiotics. No need for ventricular drain since no hydrocephalus and clinical status improving.

### Cardiac ultrasound without vegetation

### Hearing loss



### Treatment

- Until cx obtained
  - vancomycin (15 to 20 mg/kg every 8 to 12 hours) plus
  - ampicillin (2 g every 4 hours)
  - plus cefepime (2 g every 8 hours)
- OR vancomycin plus meropenem (2 g every 8 hours)
- steroids



# Assessment: #Streptococcus pneumoniae bacteremia: #Bacterial meningitis: #Recent Respiratory symptoms suggestive of pneumonia: #Low back pain: #Acute hearing loss: #neutrophilic Leukocytosis: ID ANTIMICROBIAL PLAN

D AN HIMICROBIAL PLAN Dx: Streptococcus pneumonia ventriculitis Cultures: B.C Streptococcus pneumonia Line: PICC Rx: Ceftriaxone 2 g IVPB q 12 hours Duration: 4 weeks: 12/17/2023 Labs (send to TriHealth labs only): Every Monday CBC with diff, ALT, Creatinine, ESR, C-RP. Fax all labs to ( Eallow unit: Cell (512) 084-2775 for experiment for Patheode North in 2 weeks

# FOOT Problem..... Reason for thorough physical examination

a 40 year old male who was admitted via the ED with malaise, anorexia, chills, sweats and nausea. He noted increasing pain and redness right foot that started 10 days PTA after wearing tight socks. He wife noted a foul odor that prompted a visit to the ED. He is known diabetic who did not take any medication the past few days. He was previously seen 4/21 for infection right fot with blood cx GBS 12/31/2021 with gas gangrene and OM 4th and 5th metatarsals treated with IV Zosyn. He refused amputation at that time. On admission Tmax 98.8, WBC 21.4, creatinine 0.95 and glucose 551, CRP 256. Current IV medications cefepime and vancomycin. Of note, during the last few days he has noted multiple vascular-type lesions on both hands and legs.

GBS=Group B Streptococcus










Janeway lesions Not tender Septic microemboli Soles, palms, plantar surfaces of the toe

### Osler's Nodes

Finger and toe tips Tender Cx usually negative Vasculitis







л Ц	Culture Tissue w/ Gram Stain Specimen Collected Date: 11/9/2023 7:40 PM	
Culture Tissue w/ Gram St	tain	*
STATUS Preliminary result	VISIBLE TO PATIENT No (not released)	
	VALUE	
SPECIMEN DESCRIPTION	Foot, Right	
SPECIMEN TYPE	TISSUE	3
GRAM STAIN RESULTS	Few WBCs	3
GRAM STAIN RESULTS	Moderate Gram positive cocci	3
GRAM STAIN RESULTS	Abundant Gram positive rods	3
GRAM STAIN RESULTS	Few Gram negative rods	3
GRAM STAIN RESULTS	Few Yeast	3
CULTURE RESULTS	Positive Growth !	3
CULTURE RESULTS	STAPHYLOCOCCUS AUREUS	3
CULTURE RESULTS	ENTEROCOCCUS FAECALIS	3
CULTURE RESULTS	CANDIDA ALBICANS ISOLATED	
CULTURE RESULTS	Streptococcus mitis/S. oralis	3
MICRONOTE	(NOTE) Abundant growth of Staphylococ	3
REPORT STATUS	PENDING	3
RESULTING AGENCY TRIHEALTH LABORATORY		
SPECIMEN COLLECTED 11/9/2023 7:40 PM	LAST RESULTED 11/12/2023 11:47 AM	
SPECIMEN TYPE Tissue	SPECIMEN SOURCE Foot, Right	

Clinical pictures



### Culture Blood Adult - First Set

Status: Final result Visible to patient: No (not released) Next appt: 01/24/2024 at 11:00 AM in Internal Medicine (Yvette Nei Specimen Information: Blood (Peripheral Site 1)

0 Result Notes

	8 d ago					
SPECIMEN DESCRIP- TION	BLOOD (SITE 1 PERIPHERAL)					
SPECIMEN TYPE	Blood					
GRAM STAIN RESULTS		GRAM POSITIVE COCCI IN CHAINS				
GRAM STAIN RESULTS	117084 8/2/23 1708					
GRAM STAIN RESULTS	Tested at Bethesda	North Hospita	1 10500 Montgomer	y Rd 45242		
CULTURE RESULTS	Positive Growth !!					
CULTURE RESULTS	ENTEROCOCCUS FAECAL	IS				
MICRONOTE	(NOTE) Growth of Enterococcus faecalis Tested at: Preferred Lab Partners, 1 Medical Village Drive 41017					
REPORT STATUS	08/06/2023 FINAL RE	08/06/2023 FINAL REPORT				
ORGANISM	ENTEROCOCCUS FAECAL	IS				
Susceptibility						
		Entero	coccus faecalis MIC			
Ampicillin		<=2	Sensitive <sup>1</sup>			
Chloramphenicol		<=8	Sensitive <sup>1</sup>			
Daptomycin		1	Sensitive <sup>1</sup>			
Erythromycin		>4	Resistant <sup>2</sup>			
Gentamicin Syner	gy Screen	<=500	Sensitive <sup>1</sup>			
Linezolid		1	Sensitive <sup>1</sup>			
Penicillin G		2	Sensitive <sup>1</sup>			
	otomycin Synergy Screen SUSCEPTIBLE					
Vancomycin	1 Sensitive <sup>1</sup>					
1 SUSCEPTIBLE						
DECTOTANT						



### Not this patient, however this is VRE

Sensitivity

#### ORGANISM

ENTEROCOCCUS FAECIUM

Culture & Susceptibility

### ENTEROCOCCUS FAECIUM

Antibiotic	
Ampicillin	
	Metho
Ciprofloxacin	
	Metho
Daptomycin	
	Metho
Levofloxacin	1.220.000
	Metho
Linezolid	
	Metho
Nitrofurantoin	
	Metho
Tetracycline	
	Metho
Vancomycin	

	Resistant
ethod	MIC
	Resistant
ethod:	MIC
	Sensitive
ethod:	MIC
	Resistant
ethod.	MIC
	Sensitive
ethod:	MIC
	Sensitive
ethod.	MIC

Resistant od MIC Resistant

Method: MIC


Status >8 RESISTANT Final >2 RESISTANT Final **4 SUSCEPTIBLE Final** >4 RESISTANT Final 2 SUSCEPTIBLE Final <=32 Final SUSCEPTIBLE >8 RESISTANT Final >16 RESISTANT Final PLEASE NOTE

VANCOMYCIN RESISTANCE

Microscan

# **VRE** Risk Factors

- Antimicrobial therapy
  - Parenteral and oral Vancomycin
  - Cephalosporins
- Length of hospital stay
- Immunosuppression
  - Malignancy, organ transplant, chronic renal failure
- IV Medications
  - E faecium and E faecalis
    - Linezolid
  - E faecalis
    - Daptomycin



# IV Daptomycin and Cefepime, Flagyl for anerobic coverage ID ANTIMICROBIAL PLAN Dx: MSSA bacteremia; necrotizing fasciitis Cultures: Blood culture with MSSA Line: PICC Rx: Unasyn 3 g IVPB q 6 hours or continuous infusion

# TRAVEL TO BANGLADESH.....

is a 22 year old female, with history of sleeve gastrectomy, with recent travel to bangladesh who was admitted with fever, myalgias, and abdominal pain. Patient found to have salmonella bacteremia suspicious for typhoid fever. She was started on levaquin. WBC normal. CT scan with no cholecystitis, enlarged lymh nodes.



Component	4 d ago				
SPECIMEN DESCRIP-	BLOOD (SITE 1 PERIPHERAL)				
SPECIMEN TYPE	Blood				
SRAM STAIN RESULTS	GRAM NEGATIVE RODS				
SRAM STAIN RESULTS	Preliminary critical result called to and read back by: BLISSPAUL,WHADJAH ON 12/13/23 AT 0522 BY RR				
GRAM STAIN RESULTS	Tested at Bethesda North Hospital 10500 Montgomery R 45242	Rd			
CULTURE RESULTS	Positive Growth !!				
CULTURE RESULTS	SALMONELLA SPECIES				
MICRONOTE	(NOTE) Growth of Salmonella species Tested at: Preferred Lab Partners, 1				
	Medical Village Drive 41017				
	Medical Village Drive 41017 12/15/2023 FINAL REPORT				
REPORT STATUS DRGANISM					
	12/15/2023 FINAL REPORT				
ORGANISM	12/15/2023 FINAL REPORT				
ORGANISM	12/15/2023 FINAL REPORT SALMONELLA SPECIES Salmonella species				
ORGANISM Susceptibility	12/15/2023 FINAL REPORT SALMONELLA SPECIES Salmonelia species MIC				
ORGANISM Susceptibility Ampicillin	12/15/2023 FINAL REPORT SALMONELLA SPECIES Salmonella species MIC <=8 Sensitive <sup>1</sup>				

## Assessment:

- 1. Salmonella bacteremia
- -- suspicious for typhoid
- -- about 40% resistance to flouroquinolones noted in bangladesh : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249406/#:~:text=Resistance%20genes%20in% 20the%20majority,nalidixic%20acid%20and%20ciprofloxacin%2C%20respectively.
- -- repeat blood cultures ordered
- -- will transition to cefepime 2 g IVPB q 12

43




#### Labs/Cultures: Recent Labs


Recent La	15		
	12/10/23	12/12/23	
	1327	1351	-
WBC	6.7	4.4	
HGB	12.6	12.8	
HCT	38.8	38.8	
MCV	73.0*	72.7*	
PLT	257	235	
PLT	257	235	

#### **Recent Labs**

	12/10/23 1327	12/12/23 1351
NA	134*	133*
NA K CL	3.9	3.5*
CL	101	100
CO2	22	22
AGAP	11	11
GLU	115*	113*
BUN	8	6*
CRET	0.72	0.71
CA	9.1	8.9
ALB	4.1	4.0
TP	7.6	7.5
ALT	19	38



### Procalcitonin Result



ĺ	

### () HEPATIC FUNC PANEL

Status: Final result Visible to patient: No (not released) Next appt: None

0 Result Notes

Component Ref Range & Units	2 d ago	3 d ago	4 d ago	5 d ago	7 d ago
ALK PHOSPHATASE 35 - 135 IU/L	85	95	83	92	53
TOTAL PROTEIN 6.0 - 8.0 g/dL	5.5 🗸	6.1	6.2	7.5	7.6
ALBUMIN 3.5 - 5.7 g/dL	3.0 ¥	3.4 ¥	3.2 ¥	4.0	4.1
AST 10 - 40 IU/L	79 ^	91 ^	69 🔦	66 🔦	29
ALT 10 - 60 IU/L	40	47	37	38	19
TOTAL BILIRUBIN 0.0 - 1.2 mg/dL	0.4	0.5	0.5	0.6	0.6
DIRECT BILIRUBIN 0.0 - 0.2 mg/dL	0.1	0.2 <sup>CM</sup>	0.2 °	0.2 CM	0.1 <sup>CM</sup>

Order:




HEMATOLOGY MISC	
RAPID MALARIA ANTIGEN SCREEN	12/12/23 NEGATIVE
MALARIA SLIDE REVIEW	12/12/23 NEGATIVE
MALARIA, % RBC INFECTED	12/12/23 PENDING
PLASMODIUM SPECIES	12/12/23 PENDING

### Show images for CT ABDOMEN PELVIS W CONTRAST

### Impression

Retroperitoneal and mesenteric lymphadenopathy may be reactive or related to myeloproliferative disorder. Malpositioned intrauterine device. Hepatic steatosis.

	icroscopic Slide Review	Orde
Status: Final result Visible to patient: No (not re	eleased) Next appt: None	
0 Result Notes		
Component	5 d ago	7 d ago
Ref Range & Units		
RAPID MALARIA ANTIGEN SCREEN NEGATIVE Comment Presumptive negative for	<b>NEGATIVE</b> malaria antigen. Malaria antig	NEGATIVE <sup>CM</sup> en in the sample may be below the det
2 (Z)		
limit of the test. This is an immunochromatographic	fection. Rapid screening resul rheumatoid	철생님 이상 이상 이상 이상 가슴 가지? 이 이 이 이 것 않는 이 이상 것 이가 가지? 한 것 이 이상 것 이 이 것 같아.
limit of the test. This is an immunochromatographic signs and symptoms of malarial in monitoring. Samples with positive	fection. Rapid screening resul rheumatoid	n of Plasmodium antigens in individua ts should not be used for therapeutic NEGATIVE <sup>CM</sup>



C F S A P C P C P
s
ľ
0
P
0
r
P
P
P
F
P
I P
P.
I D
T I
P
1
FFF
F
F
r P
E
E
E
r
N
4

Component Ref Range & Units	2 d ago	
SPECIMEN SOURCE, RESPIRATORY PATHOGENS	Nasopharynx	
ADENOVIRUS PCR Not Detected	Not Detected	1
CORONAVIRUS HKU1, NL63, OC43, 229E (NOT COVID Not Detected	-19) Not Detected	1
CORONAVIRUS COVID19 Not Detected	Not Detected	1
Comment Negative (Not Detected) results sole basis for treatment or other paties Testing was performed using the BioFire METAPNEUMOVIRUS PCR	ent management deci:	sions. 2.1 (F
Not Detected RHINO/ENTEROVIRUS PCR Not Detected	Not Detected	
Comment Note: This test does not differ		
FLU A (NO SUBTYPE) Not Detected	Not Detected	1
INFLUENZA A H1 Not Detected	Not Detected	1
INFLUENZA A H1 2009 Not Detected	Not Detected	1
INFLUENZA A H3 Not Detected	Not Detected	1
INFLUENZA B VIRUS PCR Not Detected	Not Detected	1
PARAINFLUENZA VIRUS PCR Not Detected	Not Detected	1
RESPIRATORY SYNCYTIAL VIRUS PCR Not Detected	Not Detected	1
BORDETELLA PERTUSSIS PCR Not Detected	Not Detected	1
B PARAPERTUSSIS Not Detected	Not Detected	1
CHLAM PNEUMONIAE Not Detected	Not Detected	1
MYCOPLASMA PNEUMONIAE PCR	Not Detected	1

# Discharged on oral Ceftin total 2 weeks

# Positive Plasmodium falciparum



Briefly 40 year old male with no significant PMH seen for <u>non-complicated malaria</u>. The patient just returned from a 2-week trip to Nigeria where he had multiple mosquito bites. He was not on prophylaxis per patient report. Is the first time he has malaria. A rapid test came back positive for *Plasmodium falciparum*, the peripheral smear is pending. He had multiple nonspecific symptoms prior to admission including fevers and chills along with extreme weakness. Initially had low blood pressure but corrected quickly with IV fluids he may have been dehydrated. The patient is on **day 2 of artemether/lumefantrine**. He feels 100% better I will like to go home tomorrow if possible. He is not in acute distress and vital signs are stable. HIV and viral studies have been negative.

RAPID MALARIA ANTIGEN	1
SCREEN	Peritive for P falsingway protein antigen
NEGATIVE	Positive for P. falciparum protein antigen.
	Differentiation between pure P. falciparum versus
	mixed Plasmodium species infection is not possible.
Comment: This is an im	munochromatographic assay for qualitative detection
of Plasmodium antigen	s in individuals with signs and symptoms of malarial
infection. Rapid scre	ening results should not be used for therapeutic
monitoring. Samples w	ith positive rheumatoid
factors may produce f	alse positive results.
Successful Call: MAL1	called 12/12/2023 08:12 AM to FERNANDEZ PENA
	((513) 865-2246/GIBSON, CHICQUETTA) by 101995. Read
Back: Yes	
MALARIA SLIDE REVIEW	POSITIVE !!
Comment: *CRITICAL VAL	UE*
MALARIA, % RBC INFECTED	2 over 5%=severe
%	
PLASMODIUM SPECIES	Plasmodium falciparum

Labs/Cult Recent La			artemether-lumefantrine (COARTEM) 20-120 mg per tablet [505113896]	
WBC	12/11/23 0949 4.7	12/12/23 0640 4.3	Dose: 4 tablet Route: Oral Frequency: Dispense Quantity: Refills:	2 times d
HGB	13.6	11.8*	Indications of Use: Malaria	
HCT MCV	41.6 80.0*	35.9* 80.2*	Sig: Take 4 tablets by mouth 2 (two) times daily. Indications: Malaria	
PLT	56*	<b>50</b> *		
	h a			
Recentla	Ins			
Recent La	12/11/23	12/12/23 0640		
NA		12/12/23 0640 136	The metions had similiant clinical	
	12/11/23 0949	0640	<ul> <li>The patient has had significant clinical</li> </ul>	
	12/11/23 0949 <b>133</b> *	0640 136	The patient has had significant clinical	
	12/11/23 0949 <b>133</b> * 3.9	0640 136 3.6	<ul> <li>The patient has had significant clinical improvement on</li> </ul>	
NA K CL	12/11/23 0949 <b>133*</b> 3.9 100	0640 136 3.6 106	improvement on	
NA K CL CO2	12/11/23 0949 <b>133*</b> 3.9 100 27	0640 136 3.6 106 25		e
NA K CL CO2 AGAP GLU BUN	12/11/23 0949 <b>133*</b> 3.9 100 27 6	0640 136 3.6 106 25 5	improvement on artemether/lumefantrine> complete the	
NA K CL CO2 AGAP GLU	12/11/23 0949 <b>133*</b> 3.9 100 27 6 <b>119*</b>	0640 136 3.6 106 25 5 <b>102</b> *	improvement on	
NA K CL CO2 AGAP GLU BUN	12/11/23 0949 <b>133*</b> 3.9 100 27 6 <b>119*</b> 15	0640 136 3.6 106 25 5 <b>102*</b> 14	improvement on artemether/lumefantrine> complete the regimen : 4 tablets (20 mg / 120 mg tabs)	as
NA CL CO2 AGAP GLU BUN CRET CA ALB	12/11/23 0949 <b>133*</b> 3.9 100 27 6 <b>119*</b> 15 1.30	0640 136 3.6 106 25 5 <b>102*</b> 14 1.03	improvement on artemether/lumefantrine> complete the regimen : 4 tablets (20 mg / 120 mg tabs) a single dose, then 4 tablets again after 8	as
NA CL CO2 AGAP GLU BUN CRET CA	12/11/23 0949 <b>133*</b> 3.9 100 27 6 <b>119*</b> 15 1.30 8.7	0640 136 3.6 106 25 5 <b>102*</b> 14 1.03 <b>8.0*</b>	improvement on artemether/lumefantrine> complete the regimen : 4 tablets (20 mg / 120 mg tabs)	as



# Artemether-lumefantrine (Coratem)

Monitor CBC/creatinine/lactic acid/LFTs/LDH/CK

Need to check for post-artemisinin delayed hemolysis one week after he stops treatment

Monitor Hct for one month post treatment


Monitor QTc and avoid QTc prolonging medications

# Does being from Mexico change your differentials? What about diet?

- 58 year old male admitted with painful bilateral hand swelling and rash that started 2-3 days PTA
- He notes fever, but no chills
- Lives with his daughter who has 5 children all in good health
- He is from Mexico but has not been there since July (5 months ago)
- He was doing landscaping, however he lost his job since he had trouble getting in the truck due to leg discomfort

- He recently noted that he lost his balance and had severe pain in his right knee. His knee remains painful-no swelling or erythema
- He denies any new detergents, lotions, etc. No recent travel. Family has two healthy dogs.
- He is not vaccinated against flu, COVID or RSV and is uncertain of other vaccines.
- He is a known ETOH, but stopped drinking 6 months ago.
- He is DM2 on insulin







- On admission Tmax 102.6
- PCT 0.17, CRP 74
- Hb 10.9
- Blood cx NGTD
- Skin biopsy pending



#### Recent Labs

The owner work			
	12/23/23	12/24/23	12/25/23
	1851	0512	0344
WBC	8.1	8.7	5.9
HGB	10.9*	9.7*	9.6*
HCT	32.1*	24.4*	25.0*
MCV	91.4	95.0	98.0*
PLT	440*	412*	453*

#### **Recent Labs**


	12/23/23	12/23/23	12/24/23	12/24/23	12/25/23
	1851	2207	0107	0512	0344
NA	118*	126*		133*	134*
K	3.0*	3.0*		2.9*	2.9*
CL	83*	92*		101	103
CO2	23	23		25	25
AGAP	12	11		7	6
GLU	804*	457*		87	105*
BUN	12	10		7*	9
CRET	1.03	0.82	( <del></del> s)	0.54*	0.68*
CA	8.1*	8.2*		8.3*	8.2*
MG			1.8		1.8
ALB	3.7				3.0*
TBIL					0.4
TP	7.4				5.9*
ALT	16			22	10

000000	CI
	W
1000000	RE
000000	HE
(Opport	HE
	M
10	M
	M
	R
	PL
12	MF
1	DI
A STREET	SE
- Decod	BA
0000000	LY
	M
	M
99990000	EC
00000000	EC
	BA
and a second	BA
1999999	ME
0000000	M
0000000	AB
	AE
1000	AB
	AB
	AB
	AB
	NF
	RE
	PC
	SN
and the second se	ST

CBC 😞	
WBC	12/28/23 7.5
RBC	12/28/23 2.59 ¥
HEMOGLOBIN	12/28/23 9.4 ¥
HEMATOCRIT	12/28/23 25.3 ¥
MCV	12/28/23 97.7 ^
мсн	12/28/23 36.4 ^
мснс	12/28/23 37.3 ^
RDW	12/28/23 11.6 ¥
PLATELET	12/28/23 588 ^
MPV	12/28/23 7.2 ¥
DIFF <	
SEGS	12/28/23 58
BAND	10/04/21 3
LYMPHOCYTES	12/28/23 25
MONOCYTES	12/28/23 13
MONOS	10/05/21 4
EOS	10/05/21 3
EOSINOPHIL	12/28/23 3
BASOPHILS	12/28/23 1 🖻
BASOS	10/05/21 0
METAMYELOCYTE	10/05/21 2
MYELOCYTE	10/05/21 1
ABS NEUTROPHIL	10/05/21 4.27
ABS. NEUTROPHIL	12/28/23 4.40
ABS LYMPHS	12/28/23 1.80
ABS MONOS	12/28/23 1.00 ^
ABSEOS	12/28/23 0.20
ABS BASOS	12/28/23 0.00
NRBC	10/05/21 2 ^
RBC MORPHOLOGY	10/03/21 Unremarkable
POLYCHROMASIA	10/04/21 MODERA 🗈
SMUDGE CELLS	09/29/21 PRESENT 🗈
STOMATOCYTES	10/05/21 MODERA 🗈

GENERAL CHEMISTRY 🖂 😞	
SODIUM	12/29/23 132 ¥
POTASSIUM	12/29/23 4.2
CHLORIDE	12/29/23 100
CO2	12/29/23 25
BLD UREA NITROGEN	12/29/23 15
CREATININE	12/29/23 0.55 ¥
GFR AFRICAN AMERICAN	10/05/21 122 🗈
GFR NON-AFRICAN AMER	10/05/21 105
ESTIMATED GFR	12/29/23 115 🖻
ANION GAP	12/29/23 7
GLUCOSE, RANDOM	12/29/23 187 ^
CALCIUM	12/29/23 8.1 ¥
PHOSPHOROUS	12/28/23 2.8
MAGNESIUM	12/28/23 1.8 🖻
LACTIC ACID	12/23/23 1.7 🖻
AMMONIA	10/02/21 86 🔺 🖻
IRON	09/29/21 52 🖻
FERRITIN	09/29/21 3,801 ^ 🗈
IRON BINDING CAP	09/29/21 Unable to ca
IRON SATURATION	09/29/21 Unable to 🗈
BETA-HYDROXYBUTYRATE	12/23/23 1.56 ^ 🖻
FOLATE	12/26/23 >20.00 🗈
VITAMIN B12	12/26/23 1,436 ^ 🖻
VITAMIN B6, PLASMA	12/25/23 23.8 🗈
VITAMIN D 25 OH	12/25/23 <5.0 ¥ 🖻
INTERPORTATION MEANING	Internet of the D

HEPATITIS A	C C				
HEPATITIS A AB IGM	12/25/23 NONREACT	ETHANOL 🔗			
HEPATITIS B					
HEP B CORE IGM	12/25/23 NONREACT	ETHANOL	12/24/23 <10	GENERAL ENDO 🛛 🖉 🔗	
HEP B SURFACE AG	12/25/23 NONREACT				
HEPATITIS C 😞		HEAVY/TRACE META 🔅		CORTISOL AM	12/28/23 12.30
HEPATITIS C AB	12/25/23 NONREA 🖻	IRON	09/29/21 52 🖻		and a substantial field of
HIV $pprox$				GLUCOSE, RANDOM	12/29/23 187 ^
HTLV I & II ABS,EIA	12/28/23 NEGATIVE	ZINC, BLOOD	12/25/23 44.4 ¥ 🖻	HEMOGLOBIN A1C	10/02/24 420 4
HIV 1/2 AB	12/25/23 NONREA			TIEMOOLODIN ATO	10/03/21 13.0 ^
	12/25/23 2.1 ^ 🖻	LEVETIRACETAM		EST AVERAGE GLUCOSE	10/03/21 326 🗈
STRONGYLOIDES ANTIBODY, IGG	12/25/23 2.1 • 🗉	LEVETIRACETAM	12/24/23 <2 ¥ 🗈		
RPR ANTIBODY	12/23/23 0.12			TSH	09/29/21 3.120 🗄
	12/23/23 0.12 E				
STREP ANTIGEN	12/26/23 POSIT ! D			MISCELLANEOUS CH 🖉	
BLOOD CULTURE		CTDCD		DETINOL OUT ON IN A	Second Second
CULTURE BLOOD ADULT	12/23/23	STREP 🛛 🖄 🖄		RETINOL (VITAMIN A)	12/25/23 0.13 ¥
	12/23/23			RETINYL, PALMITATE	12/25/23 <0.02
C DIFF 🔗		RAPID GROUP A STREP ANTIGEN	12/26/23 POSIT ! 🖻	NETHTE, FALMITATE	12/20/20 \$0.02
C DIFF COLONIZATION	12/25/23 NEGATIVE 🗈			INTERPRETATION VITAMIN A	12/25/23 See Note 🗈
SOURCE	12/25/23 Rectum			1.1942/00/02/02 10/19/17/11/17/02/02/02/02/02/02/02/02/02/02/02/02/02/	
MISCELLANEOUS CU					
SPECIMEN DESCRIPTION	12/24/23 Forearm, Left				
SPECIMEN TYPE	12/24/23 TISSUE		Comment	r J	
REPORT STATUS	12/24/23 12/29/2023		Component	5 d ago	
MRSA 😞			Ref Range & Un	its	
MRSA Result	12/25/23 NEGATIVE		PRE-ALBUMIN		
MSAUR 😞				5.4	
MRSA Result	12/25/23 NEGATIVE		20.0 - 40.0 mg/c		
MSSA RESULT	12/25/23 NEGATIVE 🗈		Commont T		-1- D



	, a ago
SPECIMEN DESCRIP- TION	BLOOD (SITE 1 PERIPHERAL)
SPECIMEN TYPE	Blood
CULTURE RESULTS	NO GROWTH AT 5 DAYS
MICRONOTE	Tested at Bethesda North Hospital 10500 Montgomery Rd 45242
REP <mark>ORT S</mark> TATUS	12/28/2023 FINAL REPORT

Collected:	12/25/23 0344
Result status:	Final
Resulting lab:	CENTRAL RECEIVING BN
Reference range	: 60.0 - 120.0 ug/dL
Value:	44.4 ¥

64



Rocky Mountain Spotted	Fever Antibodies, IgG and IgM	
Status: Final result Visible to pa	tient: No (not released) Next appt: 03/22/2024 at 02	:40 PM in Gastroenterology (Khurram
0 Result Notes		
Component		4 d ago
Ref Range & Units		and the second second
ROCKY MT SPOT FV IGG		<1:64
<1:64		241-325-31220-3
Comment: (NOTE)		
INTERPRETIVE INFORMATI	ON: Rickettsia rickettsii (Rocky Mtn.	
	Spotted Fever) Ab, IgG	
Less than 1:64	. Negative - No significant level of	
	IgG antibody detected.	
1:64 - 1:128	. Low Positive - Presence of IgG	
	Antibody detected, suggestive of	
	current or past infection.	
1:256 or greater	. Positive - Presence of IgG	
	antibody detected, suggestive of	
	current or past infection.	







### STRONGYLOIDES ANTIBODY, IGG

Collected:	12/25/23 1538
Result status:	Final
Resulting lab:	CENTRAL RECEIVING BN
Reference range:	<=0.9 IV
Value:	2.1 ^
Comment:	(NOTE) INTERPRETIVE INFORMATION: Strongyloides Ab, IgG by ELISA
	0.9 IV or less Negative - No significant level of Strongyloides IgG antibody detected.
	1.0 IVEquivocal - The Strongyloides IgG antibody result is borderline and
	therefore inconclusive. Recommend retesting the patient in 2-4 weeks, if clinically indicated.
	1.1 IV or greater Positive - IgG antibodies to Strongyloides detected, which
	may suggest current or past infection.



Strongyloidiasis is caused by infection with the soil-transmitted helminth Strongyloides stercoralis.

This organism is capable of completing its life cycle entirely within the human host, in contrast with all other soil-transmitted helminths that cannot replicate within hosts and require exogenous reinfections to sustain their life cycle.

As a consequence, infectious-stage larvae develop in the gastrointestinal tract and endogenously propagate ongoing infection. Therefore, chronic asymptomatic infection can be sustained for decades, and clinical manifestations can occur long after the initial infection. In addition, among patients with subclinical infections who subsequently become immunosuppressed, larval reproduction can lead to disseminated infection.

· Differential diagnosis is broad:

# Infectious:

- Had a fever but it would be difficult to explain the distribution of the rash with a specific bacterial infection, even though the patient had a fever, he may have a
  superimposed bacterial infection but as of now there is no isolation on blood cultures. If this is eczema patients can develop a superimposed bacterial
  infection with group A strep or Staph aureus, will screen for close 2. May need de-escalation of antibiotic therapy. Can continue coverage for SSTI until GAS MRSA is ruled out, seems unlikely with normal wbc / normal PCT / neg blood cultures / distribution of the rash
- I cannot think of any viral infection with the distribution of the rash or any viral infection that can match his symptoms. Parvovirus B19 it is a possibility when
  exposed to kids in school age but still I think that would be low in the differential based on the distribution of the rash and his symptoms, some of them
  chronic. I d expect pancytopenia and more arthralgias.
- · Fungal etiology I think will be extremely unlikely
- Parasites: Will check for strongyloidiasis given a recent trip to Mexico but 3 there is no clear recent exposure to corticosteroids and the distribution of the rash would be atypical / no eosinophilia
- Tick-borne diseases: seems unlikely (no leucopenia/thrombocytopenia, no increased LFTs, no epidemiology, its winter)
- Mycobacteria's: Unlikely. Will check a Quantiferon but this presentation is not typical of TB

### .....

# Non-infectious

- Nutritional deficiencies: To me for nutritional deficiencies are high in the differential, after having a conversation with him about his diet, his diet is very
  deficient. I think that <u>PELLAGRA</u> can be a possibility but he does not have the typical neck rash (but considering that the we are in winter it may be possible),
  does not have diarrhea, and apparently no cognitive impairment or memory loss. I think the rash in both hands may be very similar to cases that I have seen of
  pellagra, niacin deficiency is a possibility so vitamin B3 levels will be checked. <u>Zinc deficiency</u> is also another possibility that need to be checked. No clear
  signs or symptoms of scurvy.
- Dermatological diseases: An atypical presentation of eczema or psoriasis are in the differential, a punch biopsy was already done and we are waiting for the results. Porphyria is possible but I don't see much blistering (but it is distributed on sun-exposed areas)
- Autoimmune disease/paraneoplastic syndrome: Dermatomyositis or polymyositis are in the differential diagnosis when the rash and limited to both hands and periorbital but I do not see the typical "Gottron papules" or "mechanic hands". The fact that he is losing so much weight can be the manifestation sometimes of these diseases as a paraneoplastic syndrome. Will check his CK levels and a Chest X ray along with antibodies (anti-Jo-1). SLE and RA seems less likely but will get an ANA titer.
- Paraneoplastic syndrome: including Glucagonoma (had >>>> Glucose / hyperosmolar + the rash although not typical -). Other malignancies (Lung Colon -Pancreas) is worth checking for
- · Endocrine: Addison's ? (Hyponatremia / weight loss), the rash is not typical



Final Pathologic Diagnosis Skin of left forearm, punch biopsy: - Lichenoid dermatitis. See comment.

#### Comment(s)

The findings are those of a bandlike lichenoid inflammatory infiltrate within the superficial papillary dermis and extending into the mid reticular dermis. The inflammatory infiltrate is comprised of lymphomononuclear cells, eosinophils and neutrophils. A grenz zone is present with mild dermal papillary edema noted. The overlying epidermis is mildly spongiotic. The histologic differential diagnosis includes Sweet syndrome, bowel associated dermatosis, or a lichenoid drug reaction. PAS and AFB stains are performed and interpreted as negative for fungal elements and mycobacterial organisms respectively. Clinical


and microbiologic correlation are essential.



Sweet syndrome (acute febrile neutrophilic dermatosis) is an uncommon inflammatory disorder characterized by the abrupt appearance of painful, edematous, and erythematous papules, plaques, or nodules on the skin.

Fever and leukocytosis frequently accompany the cutaneous lesions.

In addition, involvement of the eyes, musculoskeletal system, and internal organs may occur.



### Start Ivermectin PO x2 days 200 ug/kg/day Send Ova & parasites in stool, may check a blood agar for serpiginous - migrating bacterial colonies to see if he has ACTIVE Strongylodiasis (serology can be a oast exposure)---> BIOHAZARD for lab workers, message sent. Follow HTLV-1 serology (predispose to Strongyloides hyperinfection syndrome and can cause rash) Aggressive Vitamin D replacement Aggressive Niacin replacement Aggressive Zinc replacement Aggressive vitamin A replacement Follow vitamin measurements pending (B3-B6) I wonder if he has GI absorption issues / malabsorption, screen for IBD / Celiac disease? / Whipple's / H.pylori ---> MALT lymphoma? · Unifying diagnosis remains unknown EGD - Colonoscopy tomorrow w Biopsies (PAS stains needed for T.whipelli) · Does he need pancreatic enzymes?



### HPI

- 51 year-old male with hx of DM2, paraplegia, complicated GU hx s/p multiple procedures, chronic bilateral percutaneous nephrostomy tube (PCN), s/p exchange, multiple medical morbidities admitted from home with onset of fever and concern for need for IV abx.
- He states he as ill a couple of days PTA, but delayed admission as his father was in hospice care.
- He was placed on Augmentin after his PCN exchange for possible UTI but developed significant diffuse drug rash.
- He was transferred to ICU the night of admission with high fevers to 104, chills and rigors.



#### Patient Lines/Drains/Airways Status

Active LINES/DRAINS/AIRWAYS

Name	Placement	Placement	Cita	Dava
Name	date	time	Site	Days
Port A Cath 06/18/23 Left	06/18/23	0312	Subclavian	1
Subclavian	44/07/00	0700		004
Colostomy LLQ	11/07/22	0700	LLQ	224
Urostomy Ileal conduit Midline;RLQ	11/07/22	0700	Midline;RLQ	224
Ureteral Drain/Stent Right ureter 10.2 Fr.	05/10/23	1516	Right ureter	39
Wound/Skin Exceptions 11/07/22 Sacrum Medial	11/07/22	0250	Sacrum	224
Wound/Skin Exceptions 11/07/22 Buttocks Mid	11/07/22	_	Buttocks	224
Wound/Skin Exceptions 11/16/22 Other (Comment) Foot Anterior;Right red large abrasion	11/16/22	1600	Foot	214
Wound/Skin Exceptions 11/16/22 Other (Comment) Knee Anterior;Right;Posterior scar tissue that was bumped on bed railing and started bleeding	11/16/22	1600	Knee	214
Wound/Skin Exceptions 06/18/23 Knee Anterior;Left	06/18/23	2300	Knee	less than 1
Nephrostomy	06/15/23	1225	Left	3
Nephrostomy	06/15/23	1225	Right	3



#### Labs/Cultures: Recent Labs

Recent La	15		
	06/18/23	06/18/23	06/19/23
1000	0440	2225	0010
WBC	10.6*		11.5*
HGB	11.8*		10.4*
HCT	37.6*	39*	33.0*
MCV	77.5*		77.5*
PLT	355		320

#### **Recent Labs**

Sa. 2012 Sector Conversion	06/18/23	06/19/23
	0418	0010
NA	131*	130*
К	4.0	4.1
CL CO2	101	102
CO2	20*	14*
AGAP	10	14
GLU	86	121*
BUN	27*	23
CRET	1.63*	1.50*
CA	9.3	8.2*
MG		1.6*
PHOS		1.8*
ALB	3.6	3.0*
TP	7.6	
ALT	33	



omponent	6 mo ago	
PECIMEN DESCRIPTION	BLOOD (SITE 1 PERIPHERAL)	
PECIMEN TYPE	Blood	
RAM STAIN RESULTS	GRAM POSITIVE COCCI	
RAM STAIN RESULTS	Preliminary critical resul	
RAM STAIN RESULTS	Tested at Bethesda North H	
ULTURE RESULTS	Positive Growth !!	
ULTURE RESULTS	STAPHYLOCOCCUS AUREUS	
IICRONOTE	(NOTE) Growth of Staphylococcus	
EPORT STATUS	06/21/2023 FINAL REPORT	
RGANISM	STAPHYLOCOCCUS AUREUS	
usceptibility		
	Staphylococcus aureus MIC	
Cefazolin	<=4 Sensitive <sup>1</sup>	
Ceftriaxone	<=4 Sensitive <sup>1</sup>	
Chloramphenicol	<=8 Sensitive <sup>1</sup>	
Ciprofloxacin	<=1 Sensitive <sup>1</sup>	
Clindamycin	<=0.25 Sensitive <sup>1</sup>	
Erythromycin	<=0.25 Sensitive <sup>1</sup>	
Gentamicin	<=1 Sensitive <sup>1</sup>	
Levofloxacin	<=0.5 Sensitive <sup>1</sup>	
Moxifloxacin	<=0.25 Sensitive <sup>1</sup>	
Oxacillin	<=0.25 Sensitive <sup>1</sup>	
Rifampin	<=1 Sensitive <sup>1</sup>	
Tetracycline	<=2 Sensitive <sup>1</sup>	
Trimethoprim + Sulfamethoxazole	<=0.5/9.5 Sensitive <sup>1</sup>	
Vancomycin	1 Sensitive <sup>2</sup>	

Allergies	Hives, Swelling	High
Has received ceftriaxon	roat swelling and hives; tolerates cephalosporins e (5/2022 and 10/2022) and cefepime in the past ( xicillin-clavulanate by PCP June 2023, broke out	8/2014)
1icafungin	Rash	Not Specified

ENTEROCOCCUS FAECALIS	Not Detected
ENTEROCOCCUS FAECIUM	Not Detected
STAPHYLOCOCCUS	Not Detected
S. AUREUS	Not Detected
S. EPIDERMIDIS	Not Detected
S. LUGDUNENSIS	Not Detected
STREPTOCOCCUS	Not Detected
S. AGALACTIAE	Not Detected
S. PNEUMONIAE	Not Detected
S. PYOGENES	Not Detected
LISTERIA MONOCYTOGENES	Not Detected
BACTEROIDES FRAGILIS (ANAEROBE)	Not Detected
ACINETOBACTER BAUMANNII	Not Detected
ENTEROBACTERIALES	Not Detected
E. CLOACAE COMPLEX	Not Detected
E. COLI	Not Detected
K. AEROGENES	Not Detected
Κ. ΟΧΥΤΟCΑ	Not Detected
K. PNEUMONIAE	Not Detected
PROTEUS	Not Detected
SALMONELLA SP.	Not Detected
S. MARCESCENS	Not Detected
HAEMOPHILUS INFLUENZAE	Not Detected
NEISSERIA MENINGITIDIS	Not Detected
PSEUDOMONAS AERUGINOSA	Not Detected
STENOTROPHOMONAS MALTOPHILIA	Not Detected
CANDIDA ALBICANS	Not Detected
CANDIDA AURIS	Not Detected
CANDIDA GLABRATA	Not Detected
CANDIDA KRUSEI	Not Detected
CANDIDA PARAPSILOSIS	DETECTED !
CANDIDA TROPICALIS	DETECTED !

#### () BLOOD CULTURE NUCLEIC ACID ID & RESISTANCE MARKERS




#### FUNGUS SUSCEPTIBILITY Status: Final result Visible to patient: Yes (not seen) Next appt: 01/24/2024 at 12: 0 Result Notes Component 6 mo ago FUNGUS SUSCEPTIBILITY SEE NOTES Comment: SEE NOTE (NOTE) Candida parapsilosis Organism identified by client YSTMIC Fluconazole 800 daily Anidulafungin 1 Suscept Micafungin 2 Suscept Surveillance blood cultures-negative Caspofungin 1 Suscept 5-Fluorocytosine 0.12 None Posaconazole 0.06 None Voriconazole 0.5 Intermed Itraconazole 0.12 None Fluconazole 64 Resist Amphotericin B 0.5 None



SPECIMEN DESCRIPTION	Urine, Indwelling Cathete	er
SPECIMEN DESCRIPTION	Tested at Bethesda North	H
SPECIMEN TYPE	Urine	
SPECIMEN TYPE	Tested at Bethesda North	H
CULTURE RESULTS	Positive Growth !	
	PSEUDOMONAS AERUGINOSA	
MICRONOTE	(NOTE) >100,000 CFU/mL Pseudomor	as
REPORT STATUS	06/21/2023 FINAL REPORT	
ORGANISM	PSEUDOMONAS AERUGINOSA	
Resulting Agency	CN	
Susceptibility		
	Pseudomonas aeruginosa MIC	
Amikacin	<=16 Sensitive <sup>1</sup>	
Aztreonam	>16 Resistant <sup>2</sup>	
Cefepime	16 Intermediate <sup>3</sup>	
Ceftazidime	>16 Resistant <sup>2</sup>	
Ceftazidime/Avibactam	8 SUSCEPTIBLE Sensitive	
Ceftolozane/Tazobactam	<=2 SUSCEPT Sensitive	
Ciprofloxacin	2 Resistant <sup>2</sup>	
Gentamicin	<=2 Sensitive <sup>1</sup>	
Imipenem	>8 Resistant <sup>2</sup>	
Levofloxacin	>4 Resistant <sup>2</sup>	
Meropenem	>8 Resistant <sup>2</sup>	
PIP Tazo	>64 Resistant <sup>2</sup>	
Tobramycin	<=2 Sensitive <sup>1</sup>	



- AVYCAZ<sup>®</sup> (ceftazidime and avibactam)
- If used for intra-abdominal infection, need to add metronidazole,



### Travel to the Amazon rainforest

- 21 year-old male w/n medical hx traveled with friends to Amazon rainforest in Brazil. He was working in the jungle there.
- He swam, ate local food and received numerous bug bites but had no animal exposure
- When he returned to US, he developed a nodular lesion on his right cheek that got progressively worse
- Lesion is painless and he has no cervical or axillary lymphadenopathy and no other lesions
- No fevers, no allergies
- Present to urgent care and was given course of doxycycline without any effect





#### Biopsy

The patient's clinical history with concern for leishmaniasis is noted. Microscopic sections show prominent superficial epidermal necrosis with marked overlying serum crust and hyperparakeratosis. Within the dermis there is a brisk mixed inflammatory infiltrate that includes numerous histiocytes filled with small round parasites with eccentrically located basophilic bodies that are positive with Giemsa stain. The organisms are negative for PAS and GMS fungal stains. These findings strongly favor leishmaniasis; however, toxoplasmosis can have a similar histologic picture. Confirmation with other clinical testing is therefore recommended.

#### Report from the CDC

est	Result
eishmania Species Identification*	
Leishmania PCR and DNA Sequencing*	L. braziliensis+
and L. (V.) peruviana.	ollowing two Leishmania species: L. (Viannia) braziliensk formed in the CDC Special Bacteriology Reference

### Leishmaniasis

- parasitic disease that is found in parts of the tropics, subtropics, and southern Europe
- classified as a neglected tropical disease (NTD)
- caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies
- several different forms of leishmaniasis in people.
  - most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow)

## Treatment

- Lesions may heal on own-often take months or longer
- Oral Impavido (Milnefosine)
  - Antiparasitic Agent
  - 50 mg TID x 28 days
  - Monitor platelets, renal, LFTs
- Disposition
  - Little change with medication
  - Referred for plastic surgery



51-year-old female who was previously admitted on 1/26/24, discharged on 1/29/24 with dx with NSTEMI. Prior to that admission, she had 18 hours of nausea and vomiting along with neck pain and palpitations. No hx of trauma or other injury.

She underwent cardiac cath on 1/29 –mild CAD and 1/28 2D echo-WNL

Called and sent back to the ED due to abnormal blood culture obtained on initial admission.


Afebrile, normal CBC, ESR, CRP. On previous admission, WBC 11.6, afebrile

She has remained afebrile and is currently in IV Unasyn.


		Order: 511309780
Status: Final result Visible to	patient: Yes (not seen) Next appt: None	
Specimen Information: Blood	(Peripheral Site 2)	
0 Result Notes		
Component	6 d ago	
SPECIMEN DESCRIPTION	BLOOD (SITE 2 PERIPHERAL)	
SPECIMEN TYPE	Blood	
CULTURE RESULTS	Positive Growth !!	
CULTURE RESULTS	EIKENELLA CORRODENS	
MICRONOTE	(NOTE) Growth of Eikenella corrodens No further workup. ***Corrected	Results Above***
	EIKENELLA CORRODENS BETA LACTAMASE Negative Tested at: Preferred Lab P	artners, 1 Medical
	Village Drive 41017	
REPORT STATUS	02/01/2024 FINAL REPORT	

### Eikenella Corrodens

- Gram-negative facultative anaerobic bacillus usually associated with human bites
- One of the HACEK organisms
  - HACEK group (Haemophilus species, Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae) includes weakly virulent, gram-negative organisms that primarily cause endocarditis
- Treatment
  - IV ampicillin-subactam
  - amoxicillin-clavulanate (Augmentin)



## The Importance of MICs Minium Inhibitory Concentration



"....Given elevated Cr and LFTs, vancomycin/gentamicin/rifampin not good option. She was transitioned to daptomycin + ceftaroline which has some evidence for treatment of PVE. However, ceftaroline is cost-prohibitive for home (\$1000/wk per case management) so she will be discharged on daptomycin monotherapy....."

Organism	Staph aureus MRSA !		
Blood Culture, Routine	1		
	POSITIVE for Isolated two of two sets CONTACT PRECAUTIONS INDICATED		
Resulting Agency	MERCY HEALTH WEST HOSPITAL LAB		
Susceptibility			
Organism Methicillin-Resistant Staphylo aureus	Antibiotic ococcus ceFAZolin	Method BACTERIAL SUSCEPTIBILITY PANEL BY MIC	Susceptibility 8 mcg/mL: Resistant
Methicillin-Resistant Staphylo aureus	ococcus clindamycin	BACTERIAL SUSCEPTIBILITY PANEL BY MIC	<=0.5 mcg/mL: Sensitive
Methicillin-Resistant Staphylo aureus	ococcus DAPTOmycin	BACTERIAL SUSCEPTIBILITY PANEL BY MIC	<=0.5 mcg/mL: Sensitive
Methicillin-Resistant Staphylo aureus	ococcus erythromycin	BACTERIAL SUSCEPTIBILITY PANEL BY MIC	>4 mcg/mL: Resistant
Methicillin-Resistant Staphylo aureus	ococcus linezolid	BACTERIAL SUSCEPTIBILITY PANEL BY MIC	2 mcg/mL: Sensitive
Methicillin-Resistant Staphylo aureus	ococcus oxacillin	BACTERIAL SUSCEPTIBILITY PANEL BY MIC	>2 mcg/mL: Resistant
Methicillin-Resistant Staphylo aureus	ococcus tetracycline	BACTERIAL SUSCEPTIBILITY PANEL BY MIC	<=4 mcg/mL: Sensitive
Methicillin-Resistant Staphylo aureus	ococcus trimethoprim-sulfamethoxazole	BACTERIAL SUSCEPTIBILITY PANEL BY MIC	<=0.5/9.5 mcg/mL: Sensitive
Methicillin-Resistant Staphylo	ococcus vancomycin	BACTERIAL SUSCEPTIBILITY PANEL BY	1 mcg/mL: Sensitive

### Two days late blood cleared



Component	7 d ago					
SPECIMEN DESCRIP- FION	BLOOD (SITE 1 PERIPHERA	L)				
SPECIMEN TYPE	Blood					
GRAM STAIN RESULTS	GRAM POSITIVE COCCI IN	CLUSTERS				
GRAM STAIN RESULTS	Preliminary critical re	sult called to an 8/2024 0835 CW	d read back by:			
SRAM STAIN RESULTS	Tested at 1999					
CULTURE RESULTS	Positive Growth !!					
CULTURE RESULTS	METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS					
MICRONOTE	(NOTE) Growth of Methicillin Preferred Lab Partners, 1 Medi					
REPORT STATUS	01/22/2024 FINAL REPORT					
DRGANISM Susceptibility	TETHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS					
	Methicillin res	istant staphylococcus aureus MIC				
Ceftaroline	<=0	.5 Sensitive <sup>1</sup>				
Chloramphenicol	<=	8 Sensitive <sup>1</sup>				
Ciprofloxacin	<=	1 Sensitive <sup>1</sup>				
Clindamycin	<=0.2	25 Sensitive <sup>1</sup>				
Daptomycin		4				
Erythromycin	2	4 Resistant <sup>2</sup>				
Gentamicin	<=	1 Sensitive <sup>1</sup>				
Oxacillin	3	2 Resistant <sup>2</sup>				
Rifampin	<=	1 Sensitive <sup>1</sup>				
Tetracycline	<=	2 Sensitive <sup>1</sup>				
Trimethoprim + S	ulfamethoxazole <=0.5/9	.5 Sensitive <sup>1</sup>				
Vancomycin		2 Sensitive <sup>3</sup>				



Minimum Inhibitory Concentration MIC) is the lowest drug concentration that prevents visible microorganism growth after overnight incubation.

#### Recommendations

	Susceptible (S)	Susceptible dose- dependent (SDD)	Resistant (R)
Daptomycin MIC	8	≤4	≥8
Recommended dosing*	1	8-12 mg/kg Q24H	8

Dose based on actual total body weight for non-obese patients. For BMI ≥ 30 use adjusted body weight. AdjBW= IBW + 0.4(TBW-IBW)



- <u>Switch Dapto (MIC = 4) to Vancomycin IV (now MIC = 2, it was 1 before); likely the MRSA is</u> on its way to be hVISA or VISA soon due to progressive cell wall thickening.
- <u>Continue Ceftaroline IV but increase q8 hs (HIGH burden of disease), MIC to Ceftaroline is</u> pending
- Ok to continue Rifampin as long as there are no significant D-D interactions (Susceptible to Rifampin) now that the burden of disease decreased (to avoid the inoculum effect and R).
- <u>Linezolid remains an option, for now BC cleared. Other options like Quinolones / TMP-SMX /</u> Tetracyclines / Clindamycin are only 2nd or 3rd line agents.
- New BC on 1/19----> Ngtd
- New BC on 1/20----> Ngtd

### VISA- vancomycin intermediate to staph aureus

### Something you don't often see



- A 35-year-old male presented to the emergency department with complaints of right leg pain, swelling, and weakness. The symptoms were preceded by an injury he had two weeks before. He reported slipping and scraping his right lower leg around the site of pain and swelling. Additionally, the patient noted worsening progressive dyspnea and light-headedness that started by the time of the injury.
  - Medical history was pertinent for irritable bowel syndrome (IBS) constipation type. The patient reported that he was following a homemade diet mostly restricting foods with highly fermentable oligo-, di-, monosaccharides, and polyols (FODMAPs) as well as other symptom triggering foods due to IBS.
- Social history was negative for alcohol use, tobacco use or illicit drug use. Family history

- Laboratory workup was notable for anemia (hemoglobin 8.9 g/dL, hematocrit 26%), leukocytosis (white blood count 14.7 thousand/mcL; neutrophil 13.20 thousand/mcL), thrombocytosis (platelets 543 thousand/mcL), low iron (iron 25 mcg/dL) and markedly low folate levels (folate <2.00 ng/mL).</li>
  - In light of patient's complaint of dyspnea, D-dimer was ordered and was found to be elevated; as a result, he underwent a computerized tomography (CT) angiogram of the chest which was negative for pulmonary embolus, pneumonia, or pulmonary edema.



- Additional workup also revealed elevated inflammatory markers (erythrocyte sedimentation rate: 38 mm/hour, C-reactive protein: 53.30 mg/L). In consideration of the laboratory results and the fever, a diagnosis of osteomyelitis was strongly suspected.
- A magnetic resonance imaging (MRI) of the right lower extremity was ordered and revealed generalized subcutaneous edema throughout the calf with a small amount of fluid tracing down the deep to the medial head gastrocnemius; ill-defined muscle edema was also noted in the anterior, lateral, and posterior compartments. Imaging results ruled out osteomyelitis; however, infectious myositis/cellulitis was suspected. In that sense, empiric antibiotic treatment for a soft tissue infection of the right lower extremity was started with oral doxycycline 200 mg per day.



- Over the next three days, the pain and swelling were more severe and no significant improvement was observed. Upon closer inspection of the skin, the patient was noted to have follicular hyperkeratosis and perifollicular hemorrhage; that in combination with his significantly restrictive diet due to IBS, raised the suspicion for vitamin C deficiency.
- An in-depth investigation was conducted in regard to patient's symptoms and dietary patterns, at which point he reported intermittent gum bleeding as well.
- Punch biopsy of the wound was performed to obtain clarity, results of which revealed dilated hair follicle containing a "corkscrew" hair with perifollicular hemorrhage and perifollicular and perivascular lymphocytic inflammation. As a result, vitamin C level was tested which was <5 µmol/L thereby confirming the diagnosis of scurvy.</li>

# Treatment


- IV vitamin C 1 g per day with significant improvement and was discharged home 4 days after in a stable condition under supplementation I vitamin C 1 g per day
- Meet with nutritionist



### Two patients for you to see

- #1 27 year old male with pain right leg and redness that has developed rather rapidly over the past day. Doesn't feel right, thus admitted via the ED.
- #2 62 year old female that has bilateral lower leg erythema that her PCP has been treating with multiple antibiotics with no improvement admitted due to "failed treatment"





### References

- Breazzano MP, Bond JB 3rd, Bearelly S, et al. American Academy of Ophthalmology Recommendations on Screening for Endogenous Candida Endophthalmitis. Ophthalmology 2022; 129:73.
- Conlon, C. C., Stein, A., Colombo, R. E., & Schofield, C. (2020). Post-artemisinin delayed hemolysis after oral therapy for P. falciparum infection. IDCases, 20, e00741
- https://www.idsociety.org/practice-guideline/practice-guidelines/#/+/0/date na dt/desc/
- Seher Kır, Sultan Sipahi, & Melda Dilek. (2021). Relationship between inflammatory markers and infection in chronic kidney disease. Cukurova Medical Journal, 46(1), 177–185.
- Shahunja, K. M., Leung, D. T., Ahmed, T., Bardhan, P. K., Ahmed, D., Qadri, F., Ryan, E. T., & Chisti, M. J. (2015). Factors Associated with Non-typhoidal Salmonella Bacteremia versus Typhoidal Salmonella Bacteremia in Patients Presenting for Care in an Urban Diarrheal Disease Hospital in Bangladesh. PLoS Neglected Tropical Diseases, 9(9), e0004066
- Wu, S.-C., Liang, C.-X., Zhang, Y.-L., & Hu, W.-P. (2020). Elevated serum procalcitonin level in patients with chronic kidney disease without infection: A case-control study. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 34(2), e23065